Eli LillyLLY
LLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Employees: 47,000
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
136% more first-time investments, than exits
New positions opened: 468 | Existing positions closed: 198
5% more funds holding
Funds holding: 3,606 [Q3] → 3,798 (+192) [Q4]
4% more repeat investments, than reductions
Existing positions increased: 1,503 | Existing positions reduced: 1,446
9% less call options, than puts
Call options by funds: $9.28B | Put options by funds: $10.1B
1.85% less ownership
Funds ownership: 83.78% [Q3] → 81.93% (-1.85%) [Q4]
13% less capital invested
Capital invested by funds: $693B [Q3] → $604B (-$88.7B) [Q4]
30% less funds holding in top 10
Funds holding in top 10: 463 [Q3] → 323 (-140) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1,038
26%
upside
Avg. target
$1,109
35%
upside
High target
$1,190
45%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Mohit Bansal 44% 1-year accuracy 12 / 27 met price target | 34%upside $1,100 | Overweight Maintained | 5 Mar 2025 |
Truist Securities Srikripa Devarakonda 36% 1-year accuracy 12 / 33 met price target | 26%upside $1,038 | Buy Maintained | 3 Feb 2025 |
Citigroup Peter Verdult 33% 1-year accuracy 1 / 3 met price target | 45%upside $1,190 | Buy Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 76 articles about LLY published over the past 30 days
Positive
Reuters
6 hours ago
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented at a major medical meeting on Sunday.
Neutral
PRNewsWire
6 hours ago
Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels
In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data were presented at the American College of Cardiology 2025 Scientific Sessions and simultaneously published in the New England Journal of Medicine (NEJM) INDIANAPOLIS , March 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the primary endpoint.i Participants who received the 16 mg and 96 mg lepodisiran doses experienced a 40.8% reduction and a 75.2% reduction in Lp(a) levels over the same time period, respectively.i Lepodisiran also met additional secondary endpoints, showing reductions in Lp(a) levels following one or two administrations of each of the three tested doses across all timepoints assessed throughout the nearly 18-month-long study.ii Lepodisiran was administered twice at each dose (16 mg, 96 mg, or 400 mg), once at baseline and at day 180, with a separate group receiving 400 mg at baseline and placebo at day 180.
Neutral
Seeking Alpha
16 hours ago
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs and product candidates relative to the rival. Dear Seeking Alpha readers, you will discover whether Novo Nordisk or Eli Lilly is a more attractive stock in the long term.
Positive
The Motley Fool
17 hours ago
1 Growth Stock With Major Catalysts on the Way to Buy and Hold
After starting 2024 strong, Eli Lilly (LLY -0.16%) did not perform well in the second half of last year. Its financial results, though solid compared to similarly sized peers, were not always up to investors' high standards for the market-leading drugmaker.
Neutral
Finbold
1 day ago
2 healthcare stocks to buy ahead of Trump's pharmaceutical tariffs
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty.
Negative
Finbold
1 day ago
2 healthcare safe bets to buy ahead of Trump's pharmaceutical tariffs
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates involved, but the decision will likely trigger more market uncertainty.
Positive
Benzinga
2 days ago
Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop
Eli Lilly & Co. (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
Neutral
CNBC Television
2 days ago
GLP-1 space will remain two player over the medium to long term, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to talk Novo Nordisk sinking on lighter-than-expected GLP-1 demand.
Neutral
Yahoo Finance
2 days ago
Here's one healthcare name this strategist says is buy, and another to avoid
In the latest Good Buy or Goodbye, Regan Capital chief investment officer Skyler Weinand joins Market Domination host Julie Hyman to break down which stock is a good buy and what stock should be avoided. Weinand recommends investing in UnitedHealth Group (UNH), as the company is trading at an attractive P/E ratio.
Negative
Market Watch
2 days ago
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update
A key European regulatory committee has recommended against approval of Eli Lilly's Kisunla, saying the benefits of the Alzheimer's disease drug don't outweigh its risks.
Charts implemented using Lightweight Charts™